Lexicon Genetics extends gene targeting technology agreement.
Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is using gene knockout technology to systematically discover the physiological functions and medical uses of genes. The Company's gene function discoveries fuel therapeutic discovery programs in cardiovascular disease, diabetes, obesity, immune disorders, neurological disease and cancer. Lexicon has established drug discovery alliances and functional genomics collaborations with leading pharmaceutical and biotechnology companies, research institutes and academic institutions throughout the world to commercialize its technology and further develop its discoveries.
Lexicon Genetics, Inc.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Boehringer Ingelheim Pharmaceuticals Inc.; OmniBank Universal|
|Publication:||BIOTECH Patent News|
|Article Type:||Brief Article|
|Date:||Mar 1, 2003|
|Previous Article:||Advanced Cell Technology revails in cloning patent dispute.|
|Next Article:||Sangamo BioSciences granted zinc finger DNA-binding protein patent.|